# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Ami Fadia reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $285 price target.
Mizuho analyst Salim Syed maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $277 to $251.
Truist Securities analyst Srikripa Devarakonda reiterates Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $...
Needham analyst Ami Fadia maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $288 to $285.
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $282 to...
Wells Fargo analyst Mohit Bansal maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and lowers the price target from $240 to...
Scotiabank analyst George Farmer maintains Biogen (NASDAQ:BIIB) with a Sector Outperform and lowers the price target from $2...